Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16030138 | 0.89 | NR1H2 (0.47) | NR1H2NR1H3 | |
| SCHEMBL16031735 | 0.84 | NR1H2 (0.43) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL5677101 | 0.81 | NR1H2 (0.59) | NR1H2NR1H3 | |
| SCHEMBL19687742 | 0.80 | NR1H2 (0.47) | NR1H2NR1H3 | |
| SCHEMBL16090783 | 0.78 | NR1H2 (0.40) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL19687703 | 0.78 | CYP3A4 (0.43) | NR1H2NR1H3 | |
| SCHEMBL19687739 | 0.77 | RORC (0.46) | — | |
| SCHEMBL14816842 | 0.75 | NR1H2 (0.45) | NR1H2NR1H3 | |
| SCHEMBL16090787 | 0.74 | NR1H2 (0.38) | NR1H2NR1H3 | |
| SCHEMBL16030540 | 0.73 | NR1H2 (0.36) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | NR1H2 4024/4885NR1H3 4252/4885GABRG2 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.